207 related articles for article (PubMed ID: 30213402)
1. Extranodal NK/T-cell lymphoma: Updates in biology and management strategies.
Yamaguchi M; Oguchi M; Suzuki R
Best Pract Res Clin Haematol; 2018 Sep; 31(3):315-321. PubMed ID: 30213402
[TBL] [Abstract][Full Text] [Related]
2. NK/T Cell Lymphoma: Updates in Therapy.
Suzuki R
Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
[TBL] [Abstract][Full Text] [Related]
3. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Yamaguchi M; Suzuki R; Oguchi M
Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
[TBL] [Abstract][Full Text] [Related]
4. Current treatment approaches for NK/T-cell lymphoma.
Yamaguchi M; Miyazaki K
J Clin Exp Hematop; 2017 Dec; 57(3):98-108. PubMed ID: 28679966
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of NK/T-cell lymphoma: current situations and prospectives].
Yamaguchi M
Rinsho Ketsueki; 2018; 59(5):588-593. PubMed ID: 29877250
[TBL] [Abstract][Full Text] [Related]
6. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
Makita S; Tobinai K
Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
[TBL] [Abstract][Full Text] [Related]
7. Extranodal natural killer/T cell lymphoma: we should and we can do more.
Ying Z; Zhu J
Chin Clin Oncol; 2015 Mar; 4(1):12. PubMed ID: 25841719
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
[TBL] [Abstract][Full Text] [Related]
9. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.
Lee S; Park HY; Kang SY; Kim SJ; Hwang J; Lee S; Kwak SH; Park KS; Yoo HY; Kim WS; Kim JI; Ko YH
Oncotarget; 2015 Jul; 6(19):17764-76. PubMed ID: 25980440
[TBL] [Abstract][Full Text] [Related]
11. [Extranodal NK/T-cell lymphoma].
Suzuki R
Nihon Rinsho; 2014 Mar; 72(3):524-30. PubMed ID: 24724414
[TBL] [Abstract][Full Text] [Related]
12. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
Yamaguchi M; Suzuki R; Kim SJ; Ko YH; Oguchi M; Asano N; Miyazaki K; Terui Y; Kubota N; Maeda T; Kobayashi Y; Amaki J; Soejima T; Saito B; Shimoda E; Fukuhara N; Tsukamoto N; Shimada K; Choi I; Utsumi T; Ejima Y; Kim WS; Katayama N
Cancer Sci; 2018 Jun; 109(6):2056-2062. PubMed ID: 29601137
[TBL] [Abstract][Full Text] [Related]
13. Current and future management of NK/T-cell lymphoma based on clinical trials.
Yamaguchi M
Int J Hematol; 2012 Nov; 96(5):562-71. PubMed ID: 23073619
[TBL] [Abstract][Full Text] [Related]
14. A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy.
Cao J; Lan S; Shen L; Si H; Zhang N; Li H; Guo R
Oncotarget; 2017 Mar; 8(12):20362-20370. PubMed ID: 27901491
[TBL] [Abstract][Full Text] [Related]
15. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
[TBL] [Abstract][Full Text] [Related]
17. Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review.
Kim SJ; Yoon SE; Kim WS
J Hematol Oncol; 2018 Dec; 11(1):140. PubMed ID: 30567593
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Asano N; Kato S; Nakamura S
Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
[TBL] [Abstract][Full Text] [Related]
19. Extranodal NK/T-cell lymphoma, nasal type: report of 15 cases.
Tababi S; Kharrat S; Sellami M; Mamy J; Zainine R; Beltaief N; Sahtout S; Besbes G
Eur Ann Otorhinolaryngol Head Neck Dis; 2012 Jun; 129(3):141-7. PubMed ID: 22321911
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and prognostic model for extranasal NK/T-cell lymphoma.
Jo JC; Yoon DH; Kim S; Lee BJ; Jang YJ; Park CS; Huh J; Lee SW; Ryu JS; Suh C
Eur J Haematol; 2012 Aug; 89(2):103-10. PubMed ID: 22553935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
